Categories: News

Liberation Labs Taps Biotech Biomanufacturing Veteran Rhys Dale to Assist with Development & Operations of Flagship Facility

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Dale has more than 20 years’ experience in developing and operating biomanufacturing facilities in the U.S. and Internationally

Rhys Dale, Site Director, Liberation Labs

Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond.Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond.
Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond.

RICHMOND, Ind., March 13, 2024 (GLOBE NEWSWIRE) — Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond. Dale has more than 20 years’ experience in developing and operating biomanufacturing facilities and biorefineries at leaders like Amyris, Applied Bio Process, and a number of food, chemical, and pharma companies around the world.

Dale has deep expertise in process conceptualization/design, technology development/scale-up, techno-economic process modeling, permitting, project development, and manufacturing. Most recently he served as Director of Process Engineering and Manufacturing at Amyris, where he worked to scale six commercial molecules at contract manufacturing organizations (CMO) and Amyris manufacturing facilities in the US, Brazil, and Europe. Prior to Amyris, Dale spent 12 years with the Bio-Process Group where he worked with project owners, technology providers, contractors, and governmental agencies in the design, development, and commercialization of technologies for biorefinery facilities and bio-products.

Liberation Labs is currently constructing a commercial-scale, purpose-built, precision fermentation biomanufacturing facility with a capacity of 600,000 liters and a fully dedicated downstream process (DSP). The plant will produce bio-based proteins and other building block ingredients at a scale and cost that will fill a pressing need among both new and established consumer packaged goods (CPG) companies and other industrial manufacturers.

“Rhys is a proven leader in scaling biotechnology through biomanufacturing development and operations, and it’s great to have him on board at this time in the project’s lifecycle,” said Mark Warner, co-founder and CEO of Liberation Labs. “He has the perfect skill set to not only bring our new facility to life but to build the operations team and deliver products to our customers.”

Dale holds a Master of Science from Purdue University; a Master of Arts from the University of North Carolina at Greensboro and a Bachelor of Arts in Biology and Economics from Earlham College.

“It’s great to be able to return home and be part of something really important for Indiana, the biotech industry at large and the country – this facility is designed to be the standard for precision fermentation and will allow for the efficient and economical production of a wide range of synthetic bio-products at the industrial scale,” said Dale. “I can’t wait to see, and help bring, this great facility to life.”

About Liberation Labs
Liberation Labs is commercializing precision fermentation with a global network of purpose-built manufacturing facilities that enable the next wave of biotechnology advancements to produce bio-based consumer products at scale. We combine modern technology with fit-for-purpose design to bring reliable and cost-effective solutions that meet customer demand across the world. More information is available at www.liberationlabs.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/805f272d-0d5b-4fbf-905a-d32e675d9354

 

CONTACT: Media Contact
John Williams, Scoville PR for Liberation Labs
+1-206-660-5503, jwilliams@scovillepr.com

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

15 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

15 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

15 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

15 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

15 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

15 hours ago